Brucella bacteraemia: clinical and laboratory observations in 160 patients.
OBJECTIVE
To describe the clinical, serological, and prognostic features of bacteraemic brucellosis in an endemic region.


METHODS
Retrospective case series of 160 patients admitted from 1983 to 1995 to a hospital providing secondary and tertiary level medical care in Saudi Arabia. All patients had positive blood cultures for Brucella species, predominantly Brucella melitensis.


RESULTS
Bacteraemia was documented in 38% of 545 cases of brucellosis admitted to our institution during the study period. The main clinical syndromes were febrile illness alone (44%) or fever with arthritis (42%). Of 68 isolates that were speciated, 93% were Brucella melitensis. Initial agglutinating antibody titre was > or =1:320 in 96% of the patients. Antimicrobial resistance of B.melitensis isolates was: co-trimoxazole, 29%; rifampicin, 3.5%; streptomycin, 0.6%; and tetracycline, 0.6%. No increase in resistance was noted over the 13-year study period. Commonly used antimicrobial regimens consisted of streptomycin plus tetracycline or rifampicin plus doxycycline given for 6 weeks. Seven patients (5%) had relapse of their symptoms after antimicrobial therapy. Three of these had infective endocarditis with repeated bacteraemia. These patients required aortic valve replacement and recovered after surgery. The remaining four patients responded to a second course of therapy.


CONCLUSIONS
Brucella bacteraemia is an acute febrile disease often associated with rheumatologic complaints. Most patients have an agglutinating antibody titre > or =1:320 and respond well to standard chemotherapy regimens with low mortality.
Memish
Z
Z
Department of Medicine, King Fahad National Guard Hospital, Riyadh, Kingdom of Saudi Arabia.
Mah
M W
MW
Al Mahmoud
S
S
Al Shaalan
M
M
Khan
M Y
MY
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology* / Q000503:physiopathology*; D017347:Brucella melitensis / Q000302:isolation & purification*; D002006:Brucellosis / Q000188:drug therapy / Q000382:microbiology* / Q000503:physiopathology*; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D012529:Saudi Arabia
D000900:Anti-Bacterial Agents